Tag: USDA

  • Designer Dogs: When Breeding for Looks Goes Too Far

    Designer Dogs: When Breeding for Looks Goes Too Far

    October 31, 2026 | Have You Heard? Original Animal Welfare Feature

    They are short, muscular, broad-chested, and sometimes built unlike any dog you have seen before. Across social media, unusually proportioned American Bully-type dogs attract attention for their oversized heads, compact frames, distinctive coats, and striking appearances.

    Some are marketed as Micro Bullies, Pocket Bullies, or Exotic Bullies. Behind their growing visibility lies a larger question: When people selectively breed dogs for a particular look, how much consideration is given to the animal’s health?

    That question comes as the federal government prepares to revisit standards for the care of dogs at regulated breeding facilities.

    Federal Officials Are Reexamining Dog Breeding Standards

    On September 21, 2026, the U.S. Department of Agriculture announced additional animal-welfare oversight measures, including plans to propose updated dog-care standards in 2027.

    The USDA said its Animal and Plant Health Inspection Service was reviewing 7,522 unique public comments concerning dog welfare. The agency also reported sending more than 2,000 regulatory reminder notices to breeding facilities and increasing efforts to identify operations that evade existing requirements.

    The federal initiative is not a ban on Exotic Bullies or other designer dogs. Rather, it reflects broader scrutiny of the treatment of animals in federally regulated facilities.

    What Exactly Is a Designer Bully?

    The term “designer dog” is often associated with intentional crossbreeding, but within the American Bully community it can also refer to selective breeding for particular physical characteristics.

    Breeders may seek a specific height, muscular build, head shape, coat color, or overall appearance. Terms such as “micro” and “exotic” are used in marketing and by some registries, but they are not universally standardized breed classifications.

    These dogs are not created by digitally modifying their DNA. Their appearances generally result from selecting breeding pairs over generations, although genetics and inherited traits can be complicated and unpredictable.

    And not every unusually built dog is necessarily unhealthy. A dog’s appearance cannot substitute for a veterinary examination.

    The Business Behind the Look

    Social media gives breeders an opportunity to showcase dogs to audiences far beyond their local communities. Videos highlighting unusual body proportions, rare-looking coats, and muscular builds can attract substantial attention.

    For some buyers, the appeal is exclusivity: owning a dog that looks different from others.

    However, popularity creates questions that prospective owners should consider. Does a breeder prioritize veterinary screening and temperament? Are the dog’s parents healthy and able to move comfortably? Are breeding decisions guided by long-term welfare or primarily by appearance?

    Without independently verified sales records, it is difficult to determine the size or profitability of the overall designer-bully market. Viral attention should not be confused with reliable industry-wide financial data.

    When Physical Traits Become Health Concerns

    Veterinary professionals have long raised concerns about breeding animals for exaggerated physical characteristics when those traits interfere with normal functions.

    Depending on a dog’s anatomy and genetics, potential problems can include difficulty breathing, orthopedic stress, restricted movement, and complications associated with inherited disorders.

    These risks should be evaluated individually. It would be inaccurate to assume every American Bully, Pocket Bully, or Exotic Bully suffers from them.

    The central issue is whether a breeding program produces dogs capable of breathing, walking, playing, reproducing, and living comfortably.

    Why the Debate Is Growing

    In May 2026, veterinary publication Vet Times reported concerns from animal-welfare advocates about the promotion of smaller bully-type dogs in the United Kingdom. Experts argued that focusing only on breed labels or size restrictions does not address irresponsible breeding and ownership practices.

    Although that debate concerns British regulations, the underlying questions extend beyond national borders: How should breeders be held accountable, and how can buyers distinguish responsible programs from those driven primarily by appearance?

    What Buyers Should Ask Before Purchasing

    • Health screening: What veterinary examinations and relevant genetic or orthopedic tests have been completed on the parents?
    • Breathing and movement: Can the dogs exercise and move comfortably without obvious distress?
    • Living conditions: Can the buyer see where the puppies are raised and meet the mother when appropriate?
    • Documentation: Are veterinary records, vaccination information, and written purchase terms available?
    • Accountability: Will the breeder answer questions about inherited health risks and provide support if problems arise?

    Prospective owners should also consider adoption and consult a veterinarian familiar with the type of dog they are considering.

    The HYH Perspective: Appearance Should Never Outweigh Welfare

    There is nothing inherently wrong with appreciating a distinctive-looking dog. Many breeders and owners care deeply about their animals.

    But a photograph, a viral video, or an impressive pedigree cannot tell the complete story of an animal’s well-being.

    As federal officials prepare to revisit animal-care standards, the conversation should extend beyond which dogs attract the most attention online.

    The more important question is whether breeding practices give those dogs the best opportunity to live healthy, comfortable lives.

    A remarkable appearance may attract the first glance. A dog’s welfare deserves the lasting attention.

    Sources and Further Reading

    Have You Heard? Original analysis based on published regulatory announcements and veterinary reporting. Featured artwork is AI-generated editorial illustration, not a photograph of an identified breeder’s dogs.

  • Lab-Grown Meat: How It Works, What’s Legal, and What It Costs

    Lab-Grown Meat: How It Works, What’s Legal, and What It Costs

    Lab-grown meat is real animal meat made from cells grown in a controlled facility instead of from a raised and slaughtered animal. The industry prefers the terms cultivated meat or cell-cultured meat. In the US, a handful of products have cleared federal review, a growing list of states have banned sales, and nothing is yet sold at true supermarket scale. Below: how it’s made, who regulates it, why costs are the central problem, and how to read the headlines.

    Haveyouheardtoday

    Stay Informed on Emerging Food Tech
    Have You Heard? curates significant stories and fresh perspectives across technology, current events, and other topics.

    Explore the latest stories

    TL;DR

    • Lab-grown meat is made by taking a small sample of animal cells and feeding them in a bioreactor until they multiply into edible tissue. It is animal meat at the cellular level, not a plant-based substitute.
    • In the US, the FDA and USDA share oversight under a formal agreement: the FDA covers cell collection, banks and growth, and USDA-FSIS takes over at harvest.
    • Several states have passed bans on selling it, and some of those are being fought in court.
    • Cost and scale are the biggest obstacles. Cells double roughly once a day, contamination can ruin a batch, and price parity depends on huge bioreactors that mostly don’t exist yet.
    • The environmental case is still unsettled. It depends heavily on the energy source and the growth medium.

    Table of Contents

    What lab-grown meat actually is

    Cultivated meat is a form of cellular agriculture. Producers isolate cells from an animal, such as muscle or fat cells, and grow them in vitro in a nutrient-rich liquid called growth medium. A Nature Food review of production economics frames the goal plainly: finding a way for industrial-scale production to reach price parity with conventional meat.

    That makes it different from three things people often mix it up with:

    • Plant-based meat. Made from soy, pea or other plant proteins. No animal cells involved.
    • Fermentation-derived protein. Uses microbes such as fungi to make protein or ingredients.
    • Hybrid products. Some cultivated products blend a small share of animal cells with plant proteins, oils and starches. That is how several of the first products reaching the market are built.

    The UK’s Food Standards Agency describes cell-cultivated products as foods made without slaughter or traditional farming, using cells isolated from animals or plants. In the UK, that also means they do not meet the legal definition of “meat”, a quirk of how hygiene law is written, which shows how new the category is for lawmakers.

    How cultivated meat is made

    The process looks less like a farm and more like a brewery or a pharmaceutical plant.

    1. Cell sourcing. A small biopsy, or a cell line already established, provides starting cells. Producers can bank these cells and reuse them, which is why regulators pay attention to the cell line itself.
    2. Growth in a bioreactor. The cells sit in a tank with growth medium: amino acids, sugars, salts, vitamins and growth factors. They multiply.
    3. Structure and differentiation. Cells are coaxed into muscle, fat or connective tissue. Some products use an edible scaffold to give texture. Ground-style products are far easier than a whole steak.
    4. Harvest and finishing. The cell mass is collected, then shaped, blended with other ingredients, cooked and packaged.

    Why speed is limited

    Popular coverage often implies a burger in days. Biology says otherwise. According to a 2025 critical review in Critical Reviews in Food Science and Nutrition, mammalian and avian cells have a natural doubling time of around 24 hours. You can’t push that much faster, so the way to increase output is bigger tanks and longer, cleaner runs.

    Why sterility is a big deal

    The same review points out a common misconception: that this food would be made in looser conditions than medicines. In biotech, antibiotics are routinely used to hold bacteria back, but they can’t be used in human food production. So producers need cleanroom standards and environmental controls similar to, or tighter than, those used in pharmaceutical manufacturing, because any microbial contamination can quickly ruin an entire batch.

    Who regulates it in the US

    The US approach is a two-agency handoff. Under a formal agreement established in March 2019, the FDA oversees cell collection, cell banks and cell growth and differentiation. The USDA’s Food Safety and Inspection Service takes over at harvest for livestock and poultry products, covering safety and labeling.

    FDA and USDA cultivated meat oversight handoff

    Before a product can reach shoppers, the company goes through an FDA pre-market consultation. The FDA’s page on human food made with cultured animal cells explains the pathway, and an inventory of completed consultations lists each food that has finished it. One recent example: in March 2025 the agency completed a consultation on food made with cultured pork fat cells from Mission Barns, stating it had no questions at that time about the company’s safety conclusion.

    A “no questions” letter is not a blanket endorsement. It means the agency reviewed the company’s data and did not object. The FDA’s role in food safety is broad, reaching well beyond novel foods; even FDA warnings about dog food show how the agency’s reach extends across what animals and people eat.

    What regulators expect from producers

    The UK’s FSA offers a useful look at how a regulator thinks about this. Under its classification and HACCP guidance, producers should build Hazard Analysis and Critical Control Point principles into the design from the beginning. Because the products are novel, the burden sits with the producer to show that its specific process, including cell line, medium and harvest method, is as safe as conventional food. The UK is also running a sandbox programme from February 2025 to February 2027 to develop specific safety and labeling guidance. That is a UK scheme, not a US rule, but US producers face the same logic.

    Where you can legally buy it in the US

    Federal clearance and local legality are two different things. According to an industry roundup, five products have cleared the joint FDA and USDA process: chicken from Upside Foods and Good Meat, Wildtype salmon, Mission Barns pork fat, and Believer Meats poultry, though Believer Meats closed not long after clearance. The same piece concludes that nothing is yet selling at commercial scale anywhere.

    On top of that sits a patchwork of state laws. One recent summary reports that Alabama, Florida, Indiana, Mississippi, Montana, Nebraska and Texas have passed laws banning the sale, manufacture or distribution of cultivated meat. Florida was first in 2024. The Indiana and Texas bans are temporary and set to expire in 2027 unless renewed. The same report says a federal appeals court upheld Florida’s ban in March 2026 after a company argued it conflicts with federal food law.

    If you want to know whether you can eat it where you live, check your state’s current law and the restaurant’s own announcements. Bans and court rulings are moving targets, and this is a general overview rather than legal advice for a business that wants to sell the product.

    Why it’s still expensive

    Why it's still expensive — overview diagram

    Cost is the hard part, and the numbers explain why.

    A techno-economic model of cultivated beef, published through the NSF Public Access Repository, estimated a cost of goods sold of $35 per kg in a 42,000 L stirred tank reactor. At 211,000 L it fell to $25 per kg, and in a 262,000 L airlift reactor to $17 per kg. The models assume annual production of 100,000,000 kg, about 0.14% of global beef output.

    Bioreactor (modeled) Modeled cost of goods sold
    42,000 L stirred tank $35/kg
    211,000 L $25/kg
    262,000 L airlift $17/kg

    Two cautions apply. These are models, not prices on a shelf, and cost of goods is not retail price. And the same paper reminds us of the “scaling gap”: most academic work uses small-scale tissue engineering methods, whereas commercial competitiveness needs bioreactors from 20,000 L to more than 200,000 L. Getting there requires breakthroughs in reactor design, cell lines that tolerate suspension, and animal-free growth media, not just bigger versions of lab methods.

    The pharma lesson

    Researchers writing in Nature Food argue that many companies are trying to scale lab-bench techniques never designed for continuous, high-volume food manufacturing, and that success may depend on methods borrowed from mature pharmaceutical bioprocessing. Some work is already pointing that way. A study with supplementary data on continuous manufacturing of cultivated chicken with an animal-free medium examines the economics of that approach in detail.

    Is it better for the environment?

    The pitch has long been lower land use, water use and emissions than livestock farming. The evidence is less tidy. A 2025 critical review by Tavan and colleagues calls for more robust, standardized life cycle assessments. Early projections were optimistic, but the real footprint depends heavily on the energy source for big bioreactors and on what’s in the growth medium, factors that simplified popular reporting often skips.

    The same review notes that more than 170 companies work in cultured meat and have attracted over US$3 billion in investment since 2019. That money was raised partly on environmental claims, which is why the claims deserve scrutiny.

    In plain terms: running a cultivation plant on clean power could look quite different from running it on a fossil-heavy grid. Anyone giving you a single percentage for “how much greener” is simplifying.

    Is it safe to eat?

    For the products that have cleared review, US regulators have looked at the cell line, the production process and the harvested product. The FDA’s consultation process is built around exactly those questions. The unknowns are less about a single bite and more about long-term, large-scale production and about allergen and nutrition questions that regulators are still writing guidance on. The UK FSA, for example, has published supplementary guidance on allergenicity and nutrition for cell-cultivated products regulated as novel foods in Great Britain.

    If you have a food allergy, a medical diet or are pregnant, ask your doctor or a registered dietitian how a new product fits your situation, and read the label for the ingredient list, which will show any plant proteins or other additions.

    Our take: separate the demo from the supply chain

    We cover a lot of technology stories at Have You Heard?, and lab-grown meat is a textbook case of a story where the demo outruns the supply chain. A tasting event, an approval letter and a funding round are all real news. None of them tells you whether a product will be on your plate at a price you’d pay.

    When a new headline lands, we’d suggest three questions. First, what exactly was approved: a hybrid product, a single ingredient like cultured fat, or a pure cell-based cut? Second, at what scale is it actually being made, in liters, not in press-release adjectives? Third, who checked the environmental claim, and which energy source were they assuming?

    We also think the ban-versus-hype framing misses the middle. The documents show a field that is technically real, regulated at the federal level, politically contested at the state level, and economically unproven. All of those can be true at once. Our job is to give you the context so you can hold that complexity without sifting through noise.

    Keep following the story

    This topic changes by the month: new approvals, new state laws, new funding, and the occasional shutdown. If you want clear explanations of fast-moving stories in tech, science, food and current events, with sources you can follow up on, browse Have You Heard? or read more about how we pick our stories.

    FAQ

    Is lab-grown meat real meat?

    Yes, in the sense that it is made of real animal cells, such as muscle or fat. It is grown in a bioreactor instead of inside an animal. It is not a plant-based substitute, though some products blend cultivated cells with plant ingredients. Legal definitions vary by country; the UK, for example, does not treat these products as “meat” for hygiene law purposes.

    Is lab-grown meat approved in the US?

    Some products are. They go through an FDA pre-market consultation and then USDA-FSIS oversight for livestock and poultry products. The FDA keeps a public inventory of completed consultations. Federal clearance does not override state bans, so availability depends on where you live.

    Why is lab-grown meat so expensive?

    Cells double only about once every 24 hours, sterile conditions must be held for long stretches, and the growth medium is costly. Models suggest that very large bioreactors are needed to approach competitive costs, as the NSF-hosted techno-economic study shows, and such plants are still rare.

    Is lab-grown meat better for the planet?

    Not automatically. Researchers say the answer depends on the energy used to run bioreactors and the makeup of the growth medium, and they call for standardized life cycle assessments before anyone leans on the sustainability claim.

    Sources